↓ Skip to main content

Cochrane Database of Systematic Reviews

Hematopoietic stem cell transplantation for Gaucher disease

Overview of attention for article published in Cochrane database of systematic reviews, October 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
105 Mendeley
Title
Hematopoietic stem cell transplantation for Gaucher disease
Published in
Cochrane database of systematic reviews, October 2017
DOI 10.1002/14651858.cd006974.pub4
Pubmed ID
Authors

Usha Rani R Somaraju, Krishna Tadepalli

Abstract

Gaucher disease is the most common lysosomal storage disorder caused by a deficiency of the enzyme glucocerebrosidase. Current treatment of the disease involves a choice from enzyme replacement therapy, substrate reduction therapy and hemotopoietic stem cell transplantation (HSCT). HSCT is a high risk procedure with possible long-term benefits in the regression of skeletal and neurological changes in people with Gaucher disease. This is an update of a previously published Cochrane Review. To determine the role of HSCT in people with Gaucher disease in relation to: mortality risk associated with the procedure; efficacy in modifying the course of the disease; and arrest or regression of neurological manifestations in neuronopathic forms (types 2 and 3). We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Inborn Errors of Metabolism Trials Register which comprises of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 19 January 2017.We also searched the websites: www.clinicaltrials.gov; WHO International Clinical Trials Registry Platform portal and www.genzymeclinicalresearch.com. Date of most recent search of these sites: 02 March 2017. All randomised, quasi-randomised and controlled clinical trials comparing stem cell transplantation with enzyme replacement therapy, substrate reduction therapy, symptomatic treatment or no treatment in people with Gaucher disease of all ages. We independently assessed trials for inclusion, however, no relevant trials were identified. Thirty two trials were identified by the searches; however, these were not suitable for inclusion in the review. HSCT is a form of treatment that offers the potential of permanent cure. However, there are no clinical trials that have assessed the safety and efficacy of this treatment in comparison to other conservative measures (enzyme replacement therapy, substrate reduction therapy) now in use.There are no trials included in the review and we have not identified any relevant trials up to March 2017. We therefore do not plan to update this review until new trials are published.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 105 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 12%
Student > Ph. D. Student 12 11%
Student > Bachelor 12 11%
Student > Master 10 10%
Student > Doctoral Student 9 9%
Other 22 21%
Unknown 27 26%
Readers by discipline Count As %
Medicine and Dentistry 29 28%
Agricultural and Biological Sciences 9 9%
Nursing and Health Professions 8 8%
Biochemistry, Genetics and Molecular Biology 7 7%
Psychology 6 6%
Other 17 16%
Unknown 29 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 October 2017.
All research outputs
#13,572,275
of 23,006,268 outputs
Outputs from Cochrane database of systematic reviews
#10,137
of 12,350 outputs
Outputs of similar age
#165,378
of 327,016 outputs
Outputs of similar age from Cochrane database of systematic reviews
#221
of 275 outputs
Altmetric has tracked 23,006,268 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,350 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.7. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,016 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 275 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.